21 results about "Withdrawal syndrome" patented technology

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Disclosed are pharmaceutical preparations comprising bromantane or an analogue of bromantane, and methods of using said preparations for pharmacotherapy to alleviate withdrawal syndrome and prevent relapse in the treatment of stimulant use disorder, to transition patients off medications that have abuse or addiction liabilities, or to facilitate extinction learning in the treatment of mental disorders.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI). vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

A treatment guidance demonstration disc for withdrawal syndrome relates to the technical field of medical auxiliary equipment, and uses a gap turntable and an auricular point disc to select acupoints; a slide rail is arranged outwardly spirally on the upper surface of the slide rail disc with its center as the center, a plurality of sliding blocks are slidably installed on the slide rail disc through the cooperation of the sliding grooves and the slide rails, the upper surfaces of the sliding blocks are drawn with action exploded views, the gear is engaged with the slide rail disc of different layers by lifting the central shaft, the rotation of the tail gear of the central shaft drives the rotation of the slide rail disc, so that the sliding blocks on the slide rail disc are pushed outward along the spirally arranged sliding grooves, and the action exploded view on the sliding block pushed out generates a continuous animation effect by rotating the device again and using the visual staying principle. The present application can conveniently realize the intuitive guidance of selecting acupoints for treatment, and can also provide demonstration guidance functions of dynamic diagram motion such as eight-sectioned exercises.

The present invention relates to a method for inducing, stimulating, and / or promoting the healing of a wound or damaged skin area, comprising topically treating a subject's skin surrounding the wound or damaged skin area with conditioned medium derived from a culture of umbilical cord mesenchymal stem cells. Similarly, the present invention relates to a method for preventing the formation and / or recurrence of wounds or damaged skin areas in a subject at risk of developing wounds or damaged skin areas, comprising topically treating the subject's skin with conditioned medium derived from a culture of umbilical cord mesenchymal stem cells. Furthermore, the present invention relates to a method for treating skin damage caused by rosacea, psoriasis, eczema, dermatitis, topical steroid withdrawal syndrome, epidermolysis bullosa, or fragile skin, comprising topically treating a subject's skin surrounding the wound or damaged skin area to be treated with conditioned medium derived from a culture of umbilical cord mesenchymal stem cells. The present invention is also directed to the conditioned medium, uses thereof, compositions comprising it, methods for producing the conditioned medium, and uses of these compositions.

To provide 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids, and methods for use thereof.SOLUTION: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.SELECTED DRAWING: None

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof, wherein - - - - -, R1, R2, R3a, R3b, R4a , R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Pharmaceutical formulations comprising buromantan or analogs of buromantan are disclosed, as well as methods of using the formulations for pharmaceutical therapy to reduce withdrawal syndrome and prevent relapse in the treatment of stimulant use disorders, to quit patients from drugs having a predisposition to abuse or addiction, or to promote regression learning in the treatment of mental disorders.

A traditional Chinese medicine compound preparation with pure herbs for detoxification and Fukang, and a preparation method thereof, wherein the traditional Chinese medicine compound preparation for detoxification and Fukang includes the detoxification preparation, Fukang preparation, as well as dryness-removing and pain-relieving preparation; its preparation method includes Die Wan manufacturing process and capsule manufacturing process, the detoxification preparation and Fukang preparation adopt the Die Wan manufacturing process, the dryness-removing and pain-relieving preparation adopt the capsule manufacturing process; the invention is a traditional Chinese medicine compound preparation with pure herbs, which is a universal type for any single drug and mixed drugs, with short treatment period, quick effect, less cost, detoxification in one week, keeping people strong and healthy in another week, and no withdrawal syndrome, no drug dependence, no toxic side effects and good anti-relapse effect; it can greatly alleviate the pain of abrupt withdrawal during the detoxification process.

Disclosed are pharmaceutical preparations comprising bromantane or an analogue of bromantane, and methods of using said preparations for pharmacotherapy to alleviate withdrawal syndrome and prevent relapse in the treatment of stimulant use disorder, to transition patients off medications that have abuse or addiction liabilities, or to facilitate extinction learning in the treatment of mental disorders.

Disclosed are pharmaceutical preparations comprising bromantane or an analogue of bromantane, and methods of using said preparations for pharmacotherapy to alleviate withdrawal syndrome and prevent relapse in the treatment of stimulant use disorder, to transition patients off medications that have abuse or addiction liabilities, or to facilitate extinction learning in the treatment of mental disorders.

The invention also refers to a method of inducing, stimulating and / or promoting healing of a wound or a damaged skin area, wherein the method comprises topically treating the skin of a subject surrounding the wound or damaged skin area with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. Equally, the invention relates to a method of preventing formation and / or recurrence of a wound or a damaged skin area in a subject being at risk of developing a wound or a damaged skin area, wherein the method comprises topically treating the skin of the subject with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. Further, the invention relates to a method of treating rosacea, psoriasis, eczema, dermatitis, topical steroid withdrawal syndrome, epidermolysis bullosa, or skin damage caused by fragile skin, wherein the method comprises topically treating the skin of a subject surrounding the wound or damaged skin area to be treated with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. The present invention is also directed to conditioned medium, uses thereof, compositions comprising the same, methods of producing the same as well as uses of these compositions.

The invention relates to the technical field of medicine, in particular to application of a pharmaceutical composition in preparation of medicine for preventing relapse of cannabis sativa, the pharmaceutical composition comprises active pharmaceutical ingredients naltrexone and risperidone and can be used for treating patients suffering from cannabis sativa addiction disorder or any condition or symptom related to the cannabis sativa addiction disorder, and further, the pharmaceutical composition can be used for preventing relapse of cannabis sativa. The medicament may be used to treat patients suffering from withdrawal syndrome during rehabilitation or detoxification from treatment of abuse of cannabis and / or patients suffering from relapse of addiction after rehabilitation or detoxification from treatment of abuse of cannabis.

The invention also relates to a method of inducing, stimulating and / or promoting healing of a wounded or injured skin area wherein the method comprises topically treating the skin of a subject, which is the skin around the wounded or injured skin area, with a conditioned medium derived from the culture of umbilical cord mesenchymal stem cells. Likewise, the present invention relates to a method of preventing formation and / or recurrence of a wounded or injured skin area in a subject at risk of developing a wounded or injured skin area wherein the method comprises topically treating the skin of the subject with a conditioned medium derived from the culture of umbilical cord mesenchymal stem cells. Furthermore, the present invention relates to a method of treating rosacea, psoriasis, eczema, dermatitis, local steroid withdrawal syndrome, epidermis bullosa or skin injury caused by fragile skin, wherein the method comprises topically treating the skin of a subject around a wound or injured skin area to be treated with a conditioned medium derived from the culture of umbilical cord mesenchymal stem cells. The invention also relates to conditioned media, uses thereof, compositions comprising the same, methods for their production and uses of these compositions.

The invention belongs to the cross technical field of biological medicine and neuropsychiatric medicine, and particularly relates to application of an SAA1 protein inhibitor in preparation of a medicine for treating methylamphetamine addiction withdrawal syndrome. The invention reveals that the mesenteric white adipose tissue plays a key role in anxiety, depression and other negative emotions induced by withdrawal of methylamphetamine by secreting SAA1 protein for the first time, and further obviously increases the drug foraging behavior and relapse risk. By inhibiting or reducing SAA1 protein expression or activity from mesenteric white fat, negative emotion related to withdrawal can be effectively relieved, so that psychological desire and relapse rate are reduced. The invention provides an inhibitor taking SAA1 protein as a target spot, an antibody, a gene silencing tool or application thereof. The inhibitor, the antibody and the gene silencing tool are used for preparing drugs or preparations for treating methylamphetamine addiction withdrawal syndrome and preventing relapse. The target and the treatment method provide a brand new way and strategy for material use disorder, especially clinical intervention of methamphetamine dependence.